Insider Selling: Artivion (NYSE:AORT) CEO Sells $2,026,500.00 in Stock

Artivion, Inc. (NYSE:AORT) CEO James Mackin sold 70,000 shares of the stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $28.95, for a total transaction of $2,026,500.00. Following the sale, the chief executive officer owned 877,275 shares of the company’s stock, valued at approximately $25,397,111.25. This represents a 7.39% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Artivion Trading Up 0.6%

Shares of Artivion stock opened at $28.16 on Friday. Artivion, Inc. has a 1 year low of $19.16 and a 1 year high of $48.25. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.51 and a current ratio of 3.47. The company has a market capitalization of $1.37 billion, a P/E ratio of -402.23 and a beta of 1.25. The company’s fifty day moving average is $25.08 and its two-hundred day moving average is $30.14.

Artivion (NYSE:AORT) last posted its quarterly earnings data on Thursday, August 6th. The company reported $0.13 EPS for the quarter. Artivion had a negative net margin of 0.67% and a positive return on equity of 6.07%. The company had revenue of $125.76 million for the quarter, compared to analyst estimates of $119.99 million. Analysts forecast that Artivion, Inc. will post 0.45 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms have commented on AORT. Wall Street Zen downgraded Artivion from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Canaccord Genuity Group lifted their target price on Artivion from $39.00 to $40.00 and gave the company a “buy” rating in a research note on Tuesday. Citigroup reissued a “market outperform” rating on shares of Artivion in a report on Tuesday, July 21st. Weiss Ratings cut Artivion from a “sell (d+)” rating to a “sell (d-)” rating in a research note on Tuesday, August 11th. Finally, Citizens Jmp decreased their price target on Artivion from $53.00 to $48.00 and set a “market outperform” rating for the company in a report on Friday, May 8th. Seven investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Artivion currently has an average rating of “Moderate Buy” and a consensus target price of $44.83.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Royal Bank of Canada boosted its holdings in Artivion by 73.1% in the 1st quarter. Royal Bank of Canada now owns 93,676 shares of the company’s stock valued at $3,430,000 after purchasing an additional 39,553 shares in the last quarter. Vanguard Group Inc. increased its position in Artivion by 4.7% during the 4th quarter. Vanguard Group Inc. now owns 3,170,089 shares of the company’s stock worth $144,588,000 after purchasing an additional 141,030 shares during the period. Orbimed Advisors LLC purchased a new position in shares of Artivion during the 1st quarter worth approximately $5,530,000. UBS Group AG raised its stake in shares of Artivion by 37.0% during the 4th quarter. UBS Group AG now owns 279,675 shares of the company’s stock worth $12,756,000 after buying an additional 75,606 shares in the last quarter. Finally, Fifth Third Bancorp lifted its holdings in shares of Artivion by 58,029.7% in the 1st quarter. Fifth Third Bancorp now owns 123,235 shares of the company’s stock valued at $4,513,000 after buying an additional 123,023 shares during the period. 86.37% of the stock is owned by hedge funds and other institutional investors.

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.